Current Headlines

  1. Sygnature Discovery Invests In High-Throughput Screening Capability
    11/4/2019

    Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services. This is backed up by its new Leadfinder compound library

  2. NuChem Therapeutics Completed The Acquisition Of Amplia Pharmatek.
    10/31/2019

    NuChem Therapeutics, a drug discovery and development contract research organization (CRO) located in Montreal, specializing in synthetic and medicinal chemistry services, has just completed the acquisition of Amplia Pharmatek, a drug discovery and development CRO with a focus on biology.

  3. Small Molecule Glue That Distinguishes Mutant From The Wild-Type HTT Protein: Potential Entry Points For Huntington's Disease Drug Discovery
    10/31/2019

    Huntington's disease (HD) is one of the four major neurodegenerative diseases that have been most extensively studied. The clinical symptoms include uncontrolled dancing-mimicking behavior (chorea), as well as cognitive deficiency and psychiatric abnormalities.

  4. Pinteon Therapeutics Launches Phase 1 Trial Of Novel Tau Antibody That Targets A Potent Driver Of Neurodegenerative Disease
    10/31/2019

    Pinteon Therapeutics recently announced the launch of a Phase 1 trial of PNT001, a novel tau antibody that uniquely targets a toxic epitope known to drive neurodegenerative disease.

  5. NanoViricides Initiates Required Dermal Sensitization And Ocular Irritation Testing Of Lead Drug Candidate Towards IND
    10/31/2019

    NanoViricides, Inc. (the "Company"), a company with novel platform technology to treat difficult and life-threatening viral diseases, reports that it has initiated dermal sensitization and ocular irritation studies that are required to support the IND application of NV-HHV-101 moving towards human clinical trials.

  6. Advanced Microscopy Reveals Unusual DNA Structure
    10/30/2019

    An advanced imaging technique reveals new structural details of S-DNA, ladder-like DNA that forms when the molecule experiences extreme tension.

  7. Empowering Drug Discovery By Evaluating Antivirals In Thousands Of Single Cells
    10/30/2019

    A new enhancement to a lab-on-a-chip device allows researchers to simultaneously observe thousands of individual cells that are infected with a virus, providing important information about infection dynamics not available using traditional methods.

  8. Eurofins Discovery Elevates Its Impact In San Diego's Innovation Ecosystem By Enrolling As A Founding Sponsor Of BioLabs, San Diego
    10/30/2019

    Eurofins Discovery, a leading partner to drug discovery and development scientists, today announced a Founding Partner sponsorship agreement with BioLabs San Diego.

  9. AffyImmune Therapeutics Announces IND Approval For A First-In-Man Trial Of Affinity-Tuned CAR-T cells For Patients With Advanced, Refractory Thyroid Cancer
    10/30/2019

    AffyImmune Therapeutics, an emerging leader in CAR-T therapies, today announced FDA approval of the company's investigational new drug (IND) application for AIC100, an affinity-tuned CAR-T cell that received Orphan designation for advanced thyroid cancer.

  10. The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
    10/30/2019

    Amgen (NASDAQ: AMGN) today announced a publication in Nature unveiling the discovery of AMG 510, a small molecule inhibitor of KRASG12C being investigated as a treatment for a variety of solid tumors with KRAS G12C mutation.